Gines Diego Miralles

CIK 1773413 · President & Head of R&D · last filed 2026-06-26

Gines Diego Miralles is a President & Head of R&D who has filed 7 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for CTNM, was dated Jun 26, 2026. Current disclosed insider exposure totals $816.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$816.1K

Companies

3

Total Filings

7

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
CTNM	Director	—	$14.16	—	$0	3	2026-06-26
ARTV	President & Head of R&D	77,500	$10.53	$816.1K	$0	2	2026-05-19
NeuBase Therapeutics, Inc. (NBSE) Delisted	Director	—	$0.38	—	$0	2	2020-09-11

Recent Filings

7 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-06-26	CTNM	Grant (A)	—	$0	EDGAR
2026-05-19	ARTV	Grant (A)	+77,500	$0	EDGAR
2025-06-26	ARTV	Grant (A)	—	$0	EDGAR
2025-06-26	CTNM	Grant (A)	—	$0	EDGAR
2025-03-17	CTNM	Grant (A)	—	$0	EDGAR
2020-09-11	NeuBase Therapeutics, Inc. (NBSE) Delisted	Grant (A)	—	$0	EDGAR
2019-07-16	NeuBase Therapeutics, Inc. (NBSE) Delisted	Grant (A)	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.